Phage Therapy (Biocontrol*): Light and Shade Visit new site : Sellanophagetherapy.blogspot.com: Receptor?

"In silico"

From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

638282387	D29p08	hypothetical protein
638282403	D29p24	minor tail subunit
638282407	D29p28	hypothetical protein
638282412	D29p33	hypothetical protein
638282415	D29p36	hypothetical protein
638282438	D29p59	hypothetical protein

638298067	Bxz2p24	gp26
638298071	Bxz2p28	gp30
638298072	Bxz2p29	gp31
638298074	Bxz2p31	gp33
638298076	Bxz2p33	gp35
638298101	Bxz2p58	gp60
638298106	Bxz2p63	gp65

	638291237	TM4_17 putative tape-measure protein
	638291247	TM4_27
	638291250	TM4_30
	638291252	TM4_32
	638291253	TM4_33
	638291264	TM4_44
	638291274	TM4_54
	638291295	TM4_75
	638291299	TM4_79
	638291306	TM4_86

E	Enterococcus faecium	Third most common cause of HCA BSI. Increasing resistance to vancomycin.
S	Staphylococcus aureus (MRSA)	Emerging resistance to current drugs and significant drug toxicities. Lack of oral agents for step-down therapy
K	Klebsiella Escherichia coli K pneumoniae	ESBL-producing organisms increasing in frequency and severity; associated with increasing mortality. K pneumoniae carbapenemases causing severe infections in LTCF. Few active agents; nothing in development
A	Acinetobacter baumannii	Increasing worldwide, recent surge reported in hospitals. Very high mortality. Carbapenem-resistant.
P	Pseudomonas aeruginosa	Increasing P. aeruginosa infections in US and worldwide. Resistant to carbapenems, quinolones, aminoglycosides
E	Enterobacter species	MDR HCA infections increasing; resistance via ESBLs, carbapenemases, and cephalosporinases

E	Enterococcus faecium
S	Staphylococcus aureus (MRSA)	+
K	Klebsiella Escherichia coli K pneumoniae
A	Acinetobacter baumannii	+
P	Pseudomonas aeruginosa	++
E	Enterobacter species

Phage Therapy (Biocontrol*): Light and Shade Visit new site : Sellanophagetherapy.blogspot.com

messaggio

New site clik on the image

"In silico"

Phage Therapy is influenced by:

Sunday 27 February 2011

Receptor?